Final Programme as at 16May, 2016
Session times are subject to changes
Sunday, 29 May 2016
08:00-17:00       Registration   
08:45-09:00 S1: Opening Ceremony
Chairs: Stefan Agewall, Norway; Basil S. Lewis, Israel
Hall A

 Introductions: Basil S. Lewis, Chairman-Elect, ESC WG on Cardiovascular Pharmacotherapy

Greetings:
Stefan Agewall, Chairman, ESC WG on Cardiovascular Pharmacotherapy
Dan Atar, Vice-President, European Society of Cardiology
Michael Glikson, President, Israel Heart Society
Michael Shechter, Chairman, Israel Heart Society WG on Cardiovascular Pharmacotherapy

09:00-10:30  S2: New Challenges in Treatment of Hypertension
Chairs: Stefan Agewall, Norway; Antonio Coca, Spain;
Yehonatan Sharabi, Israel   
Hall A
Joint Session with ESC Council on Hypertension
09:00 Best Therapy for Resistant Hypertension: The Pathway Study
Antonio Coca, Dept. of Hypertension & Vascular Risk Unit Hospital Clinic (IDIBAPS). University of Barcelona, Spain
09:20 Comparing the Results of Pharmacotherapy vs. Device Intervention in Resistant Hypertension
Sverre Kjeldsen, Dept. of Cardiology, University of Oslo Ullevaal Hospital, Norway
09:40 When to Start the Treatment of Arterial Hypertension?
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Spain
10:00 The Changing Pattern of Hypertension Treatment: Arterial Properties and Hemodynamics
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel
10:20  Q & A
10:30-11:00 Coffee Break, Networking, Exhibition Visit and Posters Viewing
11:00-12:30 S3: Hot Topics in Heart Failure
Chairs: Gad Keren, Israel; Christian Torp-Pedersen, Denmark
Hall A
 11:00 Debate: Entresto should be First Line Therapy in HFrEF
Pro: Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia
Con: Giuseppe M.C. Rosano, Cardiovascular Clinical Academic Group, St George’s Hospital NHS Trust Medical School, London, UK
 11:25 Debate: SGLT2 Inhibitors for Type 2 Diabetes Mellitus:  Do we need HF Specific Trials?
Pro: Itamar Raz, Diabetes Unit at Hadassah University Hospital, Jerusalem, Israel
Con: Claudio Ceconi, Dept. of Cardiology, University Hospital of Ferrara, Ferrara, Italy
 11:50 Debate: Beta-Blockers and Digoxin can benefit HFrEF Patients with Atrial Fibrillation
Pro: Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
Con: Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia
12:15 Obesity in Heart Failure: Update 2016
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
12:30 Light Lunch
13:00-14:00 Satellite 1: Novartis on Heart Failure
Chairs: Felipe Martinez, Argentina; Jean Marc Weinstein, Israel
Hall A
13:00 Role of Neprilysin Inhibitors in CV Disease: What can we Learn from PARADIGM?
Petar Seferovic, Dept. of Cardiology, Belgrade School of Medicine, Serbia
13:30 Heart Failure Guidelines 2016:  What is New?
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
13:45 Panel Discussion:  Which Patients and when to use Sacubitril/Valsartan (Entresto)?
Offer Amir, Tuvia Ben Gal, Israel Gotsman, Andre Keren, Avi Shotan, Israel
14:00-15:00 Satellite 2: Boehringer on Diabetes Mellitus
Chairs: Avraham Karasik, Israel
Hall A
14:00 Diabetes Therapy: From Glucocentric to Complications-Oriented Approach
Avraham Karasik, Israel
14:40 Panel Discussion: Which Patients and when to use Empagliflozin?
Rakefet Bacharach, Avraham Karasik, Yoseph Rozenman, Israel
15:00-16:00 S6: Myocardial and Pericardial Disease: A Case Based Approach to Patient Management
Chairs: Yehuda Adler, Israel; Stefan Agewall, Norway;
Andre Keren, Israel
Hall A
Joint Session with ESC Working Group on Myocardial and Pericardial Disease
15:00   Clinically Suspected Myocarditis with Heart Failure Treatment
Shemy Carasso, Baruch Padeh Medical Center, Poriya, Israel
15:20 Atrial Fibrillation, Treatment with NOAC and Pericarditis: Treatment? Follow-Up?
Daniel Monakier, Israel
15:40 Pericarditis: Treatment? Follow-Up?
Dor Lotan, Sheba Medical Center, Tel Hashomer, Israel
16:00-16:30 Coffee Break, Networking, Exhibition Visit and Posters Viewing
16:30-18:00   S7: New Directions in Heart Failure
Chairs: Stefan Agewall, Norway; Stefan Anker, Germany
Hall A
Joint Session with Heart Failure Association of the ESC
16:30   Potassium Lowering Drugs
Mitja Lainscak, Dept. of Cardiology, General Hospital Celje, Slovenia
16: 50 Iron Therapy
Stefan Anker, Dept. of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany
17:10 New Therapies for Acute Decompensated Heart Failure
Giuseppe Rosano, Cardiovascular Clinical Group, St. George’s Hospital NHS Trust Medical School, London, UK
17:40     Non-Pharmacologic Therapies for Advanced Heart Failure
Offer Amir, Dept. of Cardiology, Baruch Padeh Medical Center, Poriya, Israel
18:00-19:30 Get Together Cocktails
Monday, 30 May, 2016
08:00   Registration
08:30-09:30 S8: Gender Differences in Cardiovascular Pharmacotherapy
Chairs: Claudio Ceconi, Italy; Mady Moriel, Israel;
Zvi Vered,
Israel
Hall A
08:30 Gender Differences in Pharmacology
Thomas Walther, Dept. of Pharmacology & Therapeutics, University College Cork, Ireland
08:45 Gender Differences in Clinical Trials
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain
09:00 Gender Differences in Cardiovascular Side Effects
Giuseppe Rosano, Cardiovascular Clinical Academic Group, St George’s Hospital NHS Trust Medical School, London, UK
09:15  Gender Differences in Treatment Delivery
Avital Porter, ICCU and The Women’s Cardiac Health Clinic, Rabin Medical Center-Beilinson, and the Sackler Faculty of Medicine, Tel Aviv, Israel
09:30-10:00 S9: Special Lecture: Breaking News – ESC 2016 Prevention Guidelines
Chairs: Stefan Agewall, Norway; Yoseph Shemesh, Israel
Hall A
09:30  What is New in the 2016 European ESC Guidelines on Cardiovascular Disease Prevention?
Arno W. Hoes, University Medical Center Utrecht, The Netherlands
10:00-10:30  Coffee Break, Networking, Exhibition Visit and Posters Viewing
10:30-11:30 S10: Individualizing Antithrombotic Therapy
Chairs: L. Buryachkovskaya, Russia, Nikita Lomakin, Russia, Alexander Niessner, Austria
Hall A
Russian Scientific Inflammation Society, Central Clinical Hospital of the Presidential Department of Russian Federation
 10:30   Laboratory Monitoring of Antiplatelet Therapy
Nikita Lomakin, Russia
 10:50 Genetic Aspects of Antithrombotic Therapy
Alexey Meshkov, Russia
11:10 Role of Local Inflammation in the Development of Instent Restonosis
Zufar Gabbasov, Russia
11:30-13:00 S11: Critical Issues in Antithrombotic Therapy: 2016 Update
Chairs: Stefan Agewall, Norway; Joao Morais, Portugal;
Amit Segev, Israel
(Supported by an Unrestricted Educational Grant from AstraZeneca)
Hall A
Joint Session with ESC Working Group on Thrombosis
11:30     DAPT Duration after Stenting in Stable CAD
Sven Wassmann, Dept. of Cardiology, Isar Heart Center, Isar Klinikum, Munich, Germany
11:45 DAPT Duration after Myocardial Infarction
Sigrun Halvorsen, Dept. of Cardiology, Oslo University Hospital, Ullevaal, Norway
12:00 Antithrombotic Therapy in Patients with AF and ACS
Dan Atar, Dept. of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway
12:15 Should NOACs Totally replace VKA, Aspirin for Stroke Prevention in AF?
Joao Morais, Div. of Cardiology, Santo Andre’s Hospital, Leiria, Portugal
12:30 Reversal Strategies for Non-VK Oral Anticoagulants
Alexander Niessner, Dept. of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Austria
12:45 Light Lunch
13:30-14:30 Satellite 3: Pfizer on NOACs
Chairs: Yoseph Rozenman, Israel
 Hall A
13:30 Modern Stroke Prevention in Atrial Fibrillation: How to Risk Stratify the Patients? How to Treat the Elderly?
Dan Atar, Oslo, Norway
13:50 The Future of Stroke Prevention in NVAF: NOACs for all ?
Roy Beinart, Tel Hashomer, Israel
14:05 Which NOAC to whom? Translating the Data into Clinical Decisions
Michael Glikson, Tel Hashomer, Israel
14:20 Panel Discussion: Stroke Prevention in NVAF Patients: Challenges in Clinical Practice
13:30-14:30 Satellite 4: Amgen on Lipid Lowering
Chairs: Yaakov Henkin, Israel; Ran Kornowski, Israel
Hall B
13:30 New Era in Lipid Lowering Therapy: PCSK9 Inhibitors: Efficacy, Safety and Early Promise of CVD Event Reduction
Evan Stein, USA
14:30-16:00 S12: Intersociety Opinion: New Drugs and Therapies
Chairs:  Stefan Agewall, Norway; Michael Glikson, Israel; Felipe Martinez, Argentina
Hall A
Joint Session with International Society of Cardiovascular Pharmacotherapy
14:30  New Anti-Arrhythmics
George Dan, University of Medicine “Carol Davila”, Bucharest, Romania
14:50 New Anti-Thrombotics
Antoni Martínez Rubio, Dept. of Cardiology, University Hospital of Sabadell, Barcelona, Spain
15:10 New Drugs for Angina and CAD
Juan Tamargo, Dept. of Pharmacology, Universidad Complutense de Madrid, Madrid, Spain
15:30 New Drugs for Heart Failure
Felipe A. Martinez, Cordoba National University, Argentina
15:50 Conclusion
 14:30-16:00 S13: Focus Session: Temporal Trends, Treatments and Outcomes after ACS in Israel: The Israel National ACSIS Project
Chairs:  Zaza Iakobishvili, Israel; Ran Kornowski, Israel
Hall B
Joint Session with the Israel Heart Society Working Group for Acute Cardiac Care
14:30 ACSIS 2000-2013: Overview
Ilan Goldenberg, Sheba Medical Center and Tel Aviv University, Israel
14:50 Novel Oral P2Y12 Inhibitors Uptake: Insights from ACSIS 2013 and other Real Life Data
Roy Beigel, Israel
15:10 ACSIS 2000-2013: Reperfusion Strategies and Outcomes
Eli Lev, Rabin Medical Center and Tel Aviv University, Israel
15:30  Panel Discussion: Moshe Flugelman, Israel; Shmuel Gottlieb, Israel;
Sigrun Halvorsen, Norway; Nikita Lomakin, Russia; Joao Morais, Portugal;
Sven Wassmann, Germany
16:00 Conclusion
E-poster Presentations
1. The Level of Uric Acid in Metabolic Syndrome Patient and Way of decreasing it
Olena Gerasymenko, National University of Pharmacy, Kharkiv, Ukraine
2. In Type 2 Diabetics Insulin Therapy is Associated with Micro- But Not Macrovascular Events Independently of Clinical Risk or Coronary Artery Calcium Score – An 8 Year Follow-Up
David Halon, Dept. of Cardiovascular Medicine, Lady Davis Carmel Medical Centre and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Israel
3. Reckless Administration of QT Interval Prolonging Agents in Elderly Patients with Drug-Induced Torsade De Pointes (TdP)
Dan Justo, Internal Medicine and Geriatrics D, Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University, Israel
4. Hypertension and Comorbidity: Reality Clinical Practice Data: Blood Pressure Control
Davyd Yakhontov, Novosibirsk Medical University, Russia
5. Comparison of Antiplatelet Effects of Different Forms of Acetylsalicilicacid
Nikita Lomakin, Central Clinical Hospital of President Department of Russian Federation, Moscow, Russian Federation
 To download the congress programme click here